Present top-line HOPE-B data on 52-week bleeding rates and FIX activity
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- 22 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“top-line data to be presented in the second quarter of 2021”
What we found
Evidence strength A What the grades mean
The company presented 52-week HOPE-B data on June 22, 2021, before the June 30, 2021 deadline, covering FIX activity and bleeding reductions.
-
A uniQure N.V. 8-K filed 2021-07-27
“In June 2021, the Company announced initial 52-week post-administration Factor IX data and annualized bleeding rates (ABR) in the HOPE-B pivotal trial of etranacogene dezaparvovec” ✓ confirmed on the page
-
A uniQure N.V. 10-Q filed 2021-07-26
“On June 22, 2021, we presented new data from the HOPE-B pivotal study related to the 52-week period post-infusion.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Top-line HOPE-B data on additional co-primary endpoints
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-024796 · Corrections policy